News - Herceptin, Rituxan

Filter

Current filters:

HerceptinRituxan

Popular Filters

1 to 25 of 49 results

Pipeline innovation bodes well for systemic lupus erythematosus market

18-02-2014

While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s…

AmgenAnti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineImmuPharmaLupuzorLymphoCideMarkets & MarketingPharmaceuticalRituxanRoche

Mylan debuts Hertraz, first Herceptin biosimilar, in India

Mylan debuts Hertraz, first Herceptin biosimilar, in India

03-02-2014

US generics major Mylan has launched the world's first trastuzumab biosimilar in India. The product,…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazIndiaMarkets & MarketingMylan LaboratoriesOncologyRoche

MAb market for gastric and esophageal cancer expected to double by 2019

MAb market for gastric and esophageal cancer expected to double by 2019

18-01-2014

Due to favorable market conditions in terms of US pricing structures and the anticipated approval of…

BiotechnologyHerceptinMarkets & MarketingOncologyRoche

Celltrion’s trastuzumab biosimilar, Herzuma, approved in South Korea

16-01-2014

South Korean biopharmaceutical firm Celltrion has received approval for its cancer treatment biosimilar…

Asia-PacificBiosimilarsCellTrionGenericsHerceptinHerzumaOncologyRegulationRoche

Mylan-Biocon Herceptin biosimilar gets first Indian approval

Mylan-Biocon Herceptin biosimilar gets first Indian approval

26-11-2013

US generic major Mylan says that its partner, India-based biotechnology firm Biocon has received approval…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazMylan LaboratoriesOncologyRegulationRoche

Roche’s Gazyva slows disease worsening compared to MabThera/Rituxan

Roche’s Gazyva slows disease worsening compared to MabThera/Rituxan

07-11-2013

Swiss drug major Roche (ROG: SIX) has announced new data from the second stage of the CLL11 Phase III…

EuropeGazyvaMabTheraOncologyPharmaceuticalResearchRituxanRoche

Roche’s Gazyva gains FDA approval of CLL

Roche’s Gazyva gains FDA approval of CLL

04-11-2013

The US Food and Drug Administration late Friday approved Roche’s Gazyva (obinutuzumab), also known…

Biogen IdecBiotechnologyGazyvaGenentechMabTheraNorth AmericaobinutuzumabOncologyRegulationRituxanRoche

More highlights from European Cancer Congress from Boehringer and Roche

More highlights from European Cancer Congress from Boehringer and Roche

30-09-2013

Roche presented new results from a trial of an investigational antibody which have shown encouraging…

Boehringer IngelheimEuropeHerceptinnintedanibOncologyPharmaceuticalResearchRoche

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

26-09-2013

The US Food and Drug Administration has approved changes to the prescribing information of the immune-suppressing…

Anti-Arthritics/RheumaticsArzerraBiogen IdecGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRituxanRoche

Roche's subcutaneous Herceptin injection approved for use in UK

Roche's subcutaneous Herceptin injection approved for use in UK

24-09-2013

From today HER2-positive breast cancer patients in the UK could benefit from a faster, more efficient…

EuropeHerceptinLicensingOncologyPharmaceuticalRoche

Roche's new timesaving formulation of Herceptin approved in Europe

02-09-2013

Swiss pharma major Roche (ROG: SIX) revealed this morning (September 2) that a new injectable (subcutaneous)…

BiotechnologyEuropeHerceptinOncologyPharmaceuticalRegulationRoche

Biocad enters deal for exporting rituximab biosimilar to Turkey

22-08-2013

Biocad, one of Russia's leading biotechnology companies, has signed a definitive agreement on the export…

BiocadBiotechnologyEuropeGenericsKocak FarmaLicensingMabTheraMarkets & MarketingOncologyRituxanrituximabRoche

US firms establish strategic partnership around biosimilars

06-08-2013

Privately-held Oncobiologics has formed a broad strategic partnership with fellow USA-based inVentiv…

AvastinBiotechnologyErbituxGenericsHerceptinHumiraImmunologicalsinVentive HealthOncobiologicsOncologyProductionResearchRituxan

Roche hopes Kadcyla will replace revenue lost by Herceptin patent expiry

02-08-2013

Swiss drug major Roche (ROG: SIX) could be hit by biosimilar versions of its breakthrough HER2-positive…

EuropeFinancialHerceptinKadcylaOncologyPharmaceuticalRoche

Biogen Idec beats expectations in 2nd-qtr, helped by Tecfidera launch

25-07-2013

US biotech firm Biogen Idec (Nasdaq: BIIB) has reported second quarter 2013 total revenues of $1.7 billion,…

AvonexBiogen IdecBiotechnologyFinancialNorth AmericaRituxanTecfideraTysabri

Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer

03-05-2013

A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast…

AfinitoreverolimusHerceptinNovartisOncologyPharmaceuticalResearchRochetrastuzumab

Russia's Biocad plans to produce high-tech drugs in Brazil

19-03-2013

Biocad, one of Russia's leading biotechnology companies, plans to launch production of several of its…

AvastinBiocadBiotechnologyGenericsHerceptinMabTheraOncologyProductionRocheSouth America

HER2-positive breast cancer patients prefer faster subcutaneous administration of Herceptin to IV

15-03-2013

Results from the PrefHer (Patient Preference for Subcutaneous (SC) versus Intravenous (IV) Herceptin)…

EuropeFinancialHealthcareHerceptinOncologyPharmaceuticalRegulationRoche

1 to 25 of 49 results

Company Spotlight

Fibrotech

Fibrotech

Back to top